Activity and resistance of trastuzumab according to different clinical settings

Cancer Treatment Reviews

Volumn 38, Issue 3, 2012, Pages 212-217

  Tagliabue, Elda ^a   Campiglio, Manuela ^a   Pupa, Serenella M ^a   Ménard, Sylvie ^a   Balsari, Andrea ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; HER2; Resistance; Response to therapy; Trastuzumab

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CYTOSTASIS; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; HUMAN; METASTASIS; MONOTHERAPY; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2;

EID: 84857645689     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.002     Document Type: Review

References (65)

1. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
2. Yakes F.M., Chinratanalab W., Ritter C.A., et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
3. Molina M.A., Codony-Servat J., Albanell J., et al. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
4. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
5. Boone J.J., Bhosle J., Tilby M.J., Hartley J.A., Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009, 8:3015-3023.
6. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer I 2004, 96:739-749.
7. Trillet-Lenoir V., Freyer G., Kaemmerlen P., et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002, 75:903-908.
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411.
10. Agus D.B., Sweeney C.J., Morris M.J., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007, 25:675-681.
11. Gennari R., Ménard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655.
12. Varchetta S., Gibelli N., Oliviero B., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res 2007, 67:11991-11999.
13. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
14. Beano A., Signorino E., Evangelista A., et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008, 6:25.
15. Madarnas Y., Trudeau M., Franek J.A., et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008, 34:539-557.
16. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
17. Chumsri S., Jeter S., Jacobs L.K., et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer 2010, 10:40-45.
18. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
19. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
20. Iorfida M., Bagnardi V., Balduzzi A., et al. Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. Breast 2010, 19:128-132.
21. Mosley J.D., Keri R.A. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 2008, 1:11.
22. Mozaffari F., Lindemalm C., Choudhury A., et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007, 97:105-111.
23. Pietras R.J., Fendly B.M., Chazin V.R., et al. Antibody to her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
24. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17:2235-2249.
25. Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008, 13:515-525.
26. Legrier M.E., Oudard S., Judde J.G., et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007, 96:269-276.
27. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
28. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract 512). J Clin Oncol 2007, 25S.
29. Perez E.A., Suman V.J., Davidson N.E. Results of chemotherapy alone, with sequential or concurrent addition of 52weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009, 69:24. [suppl; abstr. 701].
30. Bedard P.L., Piccart-Gebhart M.J. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008, 8:S157-S165.
31. Azim H.A., De Azambuja E., Paesmans M., Piccart-Gebhart M.J. Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judge. J Clin Oncol 2010, 28:e353-e354.
32. Petrelli F., Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 2011, [Epub ahead of print].
33. Spielmann M., Roche H., Delozier T., et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
34. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
35. Ménard S, on behalf of the Demetra Group. Observational Demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab. J. Clin. Oncol. ASCO Annual Meeting Proceedings 26, Abstract 1062; 2008.
36. Von Minckwitz G., Dubois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
37. Cancello G., Montagna E., D'Agostino D., et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008, 10:R60.
38. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
39. Campiglio M., Bufalino R., Sandri M., et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011, 128:147-154.
40. Ratner M. Roche plans for more convenient-to-use Herceptin and Rituxan. Nat Biotechnol 2010, 28:298.
41. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
42. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277.
43. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
44. Buxant F., Anaf V., Simon P., Fayt I., Noel J.C. Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 2002, 75:1-3.
45. Calascibetta A., Cabibi D., Rausa L., et al. Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides Nucleotides Nucleic Acids 2006, 25:1193-1196.
46. Nahta R., Takahashi T., Ueno N.T., Hung M.C., Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64:3981-3986.
47. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
48. Fujita T., Doihara H., Kawasaki K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252.
49. Fujita T., Doihara H., Washio K., et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006, 17:455-462.
50. Lu C.H., Wyszomierski S.L., Tseng L.M., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13:5883-5888.
51. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
52. Fabi A., Metro G., Di Benedetto A., et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 2010, 78:141-149.
53. Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002, 62:3151-3158.
54. Mani A., Roda J., Young D., et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat 2009, 117:83-89.
55. Van Ojik H.H., Bevaart L., Dahle C.E., et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003, 63:5595-5600.
56. Moga E., Alvarez E., Canto E., et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008, 36:69-77.
57. Watanabe M., Kono K., Kawaguchi Y., et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 2010, 102:520-529.
58. Levy E.M., Sycz G., Arriaga J.M., et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 2009, 15:91-100.
59. Kawaguchi Y., Kono K., Mizukami Y., Mimura K., Fujii H. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res 2009, 29:2137-2146.
60. Anido J., Scaltriti M., Bech Serra J.J., et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006, 25:3234-3244.
61. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer I 2007, 99:628-638.
62. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007, 19:61-64.
63. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 1-11.
64. Magnifico A., Albano L., Campaner S., et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res 2009, 15:2010-2021.
65. Nakanishi T., Chumsri S., Khakpour N., et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 2010, 102:815-826.